Clinical Trials Logo

Clinical Trial Summary

This study aims to know the effectiveness of "MaRiTensi" in improving knowledge, motivation, efficacy, self-care and blood pressure control for hypertension patients. This study hypothesizes that MaRiTensi effectively increases the knowledge, motivation, self-efficacy and self-care of hypertensive patients and reduces blood pressure in the intervention group compared to the control group. Respondent recruitment is as follows: 1. The respondent candidate will be identified based on data on record medical 2. Appropriate respondent candidates' criteria inclusion and exclusion contacted for given informed consent 3. Prospective respondents who are willing to participate and fulfill the criteria for pressure blood moment measurement will request signed consent 4. Respondents fill in the basic data and recapitulate by the assistant researcher 5. Done randomization for allocation of group interventions and group control 6. Respondents given envelope closed (using sequentially numbered, opaque sealed envelopes (SNOSE) method ) 7. Respondents' group intervention was given maintenance by Hospital or health center standard-added intervention using MaRiTensi by conditions; meanwhile, group control was provided care by Hospital or health center standards.


Clinical Trial Description

Participants will be separated into two groups. 1. Respondents who have given consent will be given two questionnaires 2. Intervention group respondents will be given intervention for 12 weeks 3. Control group respondents will receive services according to the hospital or health center standards. Respondents will be asked to complete a questionnaire for the first evaluation during the first week of week six and to fill out a questionnaire for the final assessment in week 12. Interventions in the form of utilizing "MaRiTensi" by the intervention group are given with the following conditions: 1. Intervention group and control group respondents filled out the Indonesian Version of the hypertension knowledge-level scale (HK-LS) questionnaire and the Indonesian Version of the Hypertension Self-care Profile (HBP-SCP) 2. Respondents were given a password to enter their data and log in to the "MaRiTensi" application. 3. Respondents will be given a simple and easy-to-understand tutorial on how to use "MaRiTensi." 4. Respondents measure blood pressure at least twice a week according to standards and record the results in the application 5. Respondents utilized every feature in MaRiTensi according to the needs of each respondent, including the question-and-answer feature 6. Respondents will be evaluated by telephone every two weeks by a research assistant to determine whether the respondent is following the intervention according to the procedure. Respondents who did not comply with the system were classified as lost follow-up 7. After using the "MaRiTensi" application, a post-test will be carried out at week six and week 12 using the Indonesian Version of the hypertension knowledge-level scale (HK-LS) and the Indonesian Version of the Hypertension Self-care Profile (HBP-SCP) questionnaire. Data analysis in the third phase of the research was carried out by: 1. Editing Data originating from filling out the Indonesian Version of the hypertension knowledge scale (HK-LS) questionnaire and the Indonesian Version of the Hypertension Self-care Profile (HBP-SCP), as well as recording blood pressure in the application, will be examined for completeness, if there is incomplete data then will be asked back to the respondent to complete it. 2. Coding Coding will be provided for each questionnaire filled by respondents, especially for quantitative data according to the data scale. Coding is given according to the provisions in filling out the questionnaire (attached) 3. Tabulating Tabulating is done to convey respondents' demographic data in the third research and data on blood pressure, knowledge, motivation, self-efficacy, and self-care of hypertensive patients, as well as the results of the effectiveness analysis of "MaRiTensi" on these variables. The data will be analyzed statistically using the paired t-test to analyze the first and second pre-test and post-test results. Comparison between the intervention and control groups will be analyzed by independent t-test. The first and second post-test outcome data will be subjected to an ANOVA test. All databases will be stored by researchers and validated by assessors, managed in a folder with a password so that not all teams can open it. Data analysis was carried out by the analyst, who performed it in a hidden manner, and the researcher will accept the data processing results for analysis to continue. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06049862
Study type Interventional
Source Gadjah Mada University
Contact Chatarina S Widyastuti, Sp.Kep.M.B
Phone +62 813-2884-2319
Email chatarinasetyawidyastuti0675@mail.ugm.ac.id
Status Recruiting
Phase N/A
Start date October 11, 2023
Completion date April 2024

See also
  Status Clinical Trial Phase
Completed NCT00573742 - Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients N/A
Recruiting NCT06208072 - The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone. N/A
Not yet recruiting NCT05917275 - Multi-Omics to Predict the Blood Pressure Response to Antihypertensives Phase 4
Completed NCT00819104 - A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components Phase 4
Not yet recruiting NCT06091176 - Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension N/A
Recruiting NCT01742702 - HaemoDYNAMICs in Primary and Secondary Hypertension
Recruiting NCT02817204 - Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients(EXCAVATION-CHN1) Phase 3
Completed NCT00794885 - China Stroke Primary Prevention Trial Phase 4
Active, not recruiting NCT04381520 - Heat-sensitive Moxibustion Self-administration in Patients in the Community With Primary Hypertension: Protocol for a Multi-center, Pragmatic, Non-randomized Trial N/A
Completed NCT00865501 - Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease Phase 3
Active, not recruiting NCT04788563 - A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community N/A
Completed NCT02184858 - Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension Phase 4
Completed NCT03105687 - Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake N/A
Completed NCT01392534 - Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting N/A
Active, not recruiting NCT03015311 - Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients N/A
Enrolling by invitation NCT03470974 - The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension N/A
Active, not recruiting NCT01844570 - Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research N/A
Completed NCT01241487 - A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy Phase 4
Completed NCT00882947 - Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) Phase 4
Active, not recruiting NCT03310684 - Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)